222 related articles for article (PubMed ID: 870189)
21. Thymidine arrest and synchrony of cellular growth in vivo.
Kufe DW; Egan EM; Rosowsky A; Ensminger W; Frei E
Cancer Treat Rep; 1980; 64(12):1307-17. PubMed ID: 7471121
[TBL] [Abstract][Full Text] [Related]
22. A Phase 1 study of high doses of aminopterin with leucovorin rescue in patients with advanced metastatic tumors.
Glode LM; Pitman SW; Ensminger WD; Rosowsky A; Papathanasopoulos N; Frei E
Cancer Res; 1979 Sep; 39(9):3707-14. PubMed ID: 383286
[TBL] [Abstract][Full Text] [Related]
23. Weekly methotrexate-calcium leucovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkin's lymphoma.
Pitman SW; Frei E
Cancer Treat Rep; 1977 Jul; 61(4):695-701. PubMed ID: 18282
[TBL] [Abstract][Full Text] [Related]
24. Reversal of methotrexate inhibition of colony growth of L1210 leukemia cells in semisolid medium.
Nederbragt H; Uitendaal MP; van der Grint L; Leyva A; Pinedo HM
Cancer Res; 1981 Mar; 41(3):1193-8. PubMed ID: 6970074
[TBL] [Abstract][Full Text] [Related]
25. Thymidine as a kinetic and biochemical modulator of 1-beta-D-arabinofuranosylcytosine in human acute nonlymphocytic leukemia.
Blumenreich MS; Chou TC; Andreeff M; Vale K; Clarkson BD; Young CW
Cancer Res; 1984 Feb; 44(2):825-30. PubMed ID: 6692380
[TBL] [Abstract][Full Text] [Related]
26. Early recognition of patients with decreased methotrexate clearance following high-dose methotrexate infusion therapy.
Ikeda H; Kihira K; Kuwata N; Arai S; Kimura Y; Miyake K; Kitaura T; Fujimura K; Kuramoto A; Fukuchi H
Hiroshima J Med Sci; 1996 Jun; 45(2):57-62. PubMed ID: 8810132
[TBL] [Abstract][Full Text] [Related]
27. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
28. Methotrexate infusion and folinic acid as primary therapy for nonmetastatic and low-risk metastatic gestational trophoblastic tumors. 15 years of experience.
Garrett AP; Garner EO; Goldstein DP; Berkowitz RS
J Reprod Med; 2002 May; 47(5):355-62. PubMed ID: 12063874
[TBL] [Abstract][Full Text] [Related]
29. Potential for methotrexate exposure through contamination during parenteral use as an immunosuppressant.
Wong LS; Tymms KE; Buckley NA
Intern Med J; 2009 Jun; 39(6):379-83. PubMed ID: 19580617
[TBL] [Abstract][Full Text] [Related]
30. Clinical and pharmacological evaluation of triazinate in humans.
Skeel RT; Cashmore AR; Sawicki WL; Bertino JR
Cancer Res; 1976 Jan; 36(1):48-54. PubMed ID: 1248009
[TBL] [Abstract][Full Text] [Related]
31. [Cerebrospinal fluid methotrexate level in children treated with medium-high and high doses of the drug].
Wysocki M; Balcar-Boroń A; Krzyzanowski M; Szadujkis-Szadurski L; Ozyński T; Nowaczyk-Michalak A
Acta Haematol Pol; 1992; 23(3):185-90. PubMed ID: 1492543
[TBL] [Abstract][Full Text] [Related]
32. Significance of the 48-hour plasma level in high-dose methotrexate regimens.
Perez C; Wang YM; Sutow WW; Herson J
Cancer Clin Trials; 1978; 1(2):107-11. PubMed ID: 316368
[TBL] [Abstract][Full Text] [Related]
33. [Studies on high-dose methotrexate with citrovorum factor rescue therapy in children: analysis of bone marrow cell kinetics by flow cytometry].
Tsurusawa M; Sasaki K; Matsuoka H; Katano N; Fujimoto T
Gan To Kagaku Ryoho; 1985 Sep; 12(9):1827-32. PubMed ID: 3876075
[TBL] [Abstract][Full Text] [Related]
34. Phase I clinical and pharmacological study of thymidine (NSC 21548) and cis-diamminedichloroplatinum(II) in patients with advanced cancer.
Schilsky RL; O'Laughlin K; Ratain MJ
Cancer Res; 1986 Aug; 46(8):4184-8. PubMed ID: 3731086
[TBL] [Abstract][Full Text] [Related]
35. A phase I study of swainsonine in patients with advanced malignancies.
Goss PE; Baptiste J; Fernandes B; Baker M; Dennis JW
Cancer Res; 1994 Mar; 54(6):1450-7. PubMed ID: 8137247
[TBL] [Abstract][Full Text] [Related]
36. Clinical phase I-II and pharmacokinetic study of high-dose thymidine given by continuous intravenous infusion.
Chiuten DF; Wiernik PH; Zaharko DS; Edwards L
Cancer Res; 1980 Mar; 40(3):818-22. PubMed ID: 7471098
[TBL] [Abstract][Full Text] [Related]
37. Calculated versus measured creatinine clearance for dosing methotrexate in the treatment of primary central nervous system lymphoma.
Gerber DE; Grossman SA; Batchelor T; Ye X
Cancer Chemother Pharmacol; 2007 May; 59(6):817-23. PubMed ID: 16972068
[TBL] [Abstract][Full Text] [Related]
38. [Effects of hydration on plasma concentrations of methotrexate in patients with osteosarcoma treated with high doses of methotrexate].
Ferrari S; Orlandi M; Avella M; Caldora P; Ferraro A; Ravazzolo G; Bacci G
Minerva Med; 1992 May; 83(5):289-93. PubMed ID: 1589134
[TBL] [Abstract][Full Text] [Related]
39. Phase I clinical study with pharmacokinetic analysis of 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC 286193) administered as a five-day infusion.
Trump DL; Tutsch KD; Koeller JM; Tormey DC
Cancer Res; 1985 Jun; 45(6):2853-8. PubMed ID: 3986812
[TBL] [Abstract][Full Text] [Related]
40. Antineoplastic agents: high-dose methotrexate and citrovorum factor rescue.
Sadée W
Ther Drug Monit; 1980; 2(2):177-85. PubMed ID: 6762711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
